The importance of pharmacogenetic tests in evaluation of the effectiveness of methotrexate treatment in rheumatoid arthritis (part 1)

摘要: Methotrexate (MTX) is still the gold standard in treatment of rheumatoid arthritis and used worldwide more than 0.5 million patients with RA. Much hope currently associated individualization therapy provided to RA patients. The search underway for biochemical clinical markers that would be useful predicting good response MTX therapy. Along factors, genetic predisposition may also helpful. Polymorphism genes participating metabolism affect drug’s efficacy rate adverse effects. Pharmacogenetic studies contribute effective There are many potential enzymes transport proteins present polymorphic forms, which involved into cell, its elimination from cell. a chance future through individualized we will able customize (type drug, dose, route administration) molecular subtype disease genotype patient. Patients specific type polymorphism require frequent monitoring safety treatment. Note, however, only one factors contributing differences pharmacotherapy individual